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Abstract
The purpose of this chapter is to examine the various treatment strategies used 
to manage neovascular age-related macular degeneration (nAMD). The chapter 
will focus on the three main strategies including fixed interval dosing, as needed 
Pro-Re-Nata (PRN) treatment and Treat-and-Extend (TAE), with its variant the 
Treat-Extend-Stop (TES) protocol. We will discuss the visual results of randomized 
clinical trials and retrospective studies using these methodologies and compare their 
outcomes, the pros and cons of each treatment strategy, as well as the underlying 
mechanisms that may explain these differences. The results of long-term extension 
trials following landmark randomized clinical studies and other long-term retrospec-
tive studies will also be compared to studies using a fixed interval dosing or the TAE/
TES method. We will also focus on the visual results of the TES protocol and examine 
recurrence rates, proposing a definition of the recurrence of choroidal neovascu-
larization (CNV) versus increased disease activity. These topics discussed will help 
optimize anti-VEGF treatment regimens for patients with nAMD over the long term.
Keywords: neovascular age-related macular degeneration (nAMD), anti-vascular 
endothelial growth factor (anti-VEGF), treat-extend-stop (TES), long-term 
management, recurrence
1. Introduction
Age-related macular degeneration (AMD) continues to be the leading cause of 
non-preventable blindness in the world and is the most frequent cause of blindness in 
industrialized nations [1, 2]. With an ever-aging population and age itself as the chief 
risk factor for the development of AMD, the burden of disease is expected to rise [3, 4]. 
Advanced AMD is defined by the presence of geographic atrophy or new onset of aber-
rant vessel growth from the underlying choroid, termed choroidal neovascularization 
(CNV) [5]. The development of CNV may lead to secondary subretinal or sub-retinal 
pigmented epithelial (RPE) hemorrhage or serous exudation, followed by fibrosis and 
scarring [5]. The degenerative form of the disease, “dry macular degeneration”, may 
convert to the neovascularization form, “wet macular degeneration”, at a rate of about 
10–15% [6]. The natural disease course of nAMD over the long term is poor. Jager 
et al. demonstrated that at 2 years, patients lost on average 4 Early Treatment Diabetic 
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Retinopathy Study (ETDRS) lines [6]. They also found at baseline 20% of patients had 
20/200 vision or worse, but at the end of 3 years, that percentage had increased to 76% 
of patients with vision 20/200 or worse [6].
Mitigating aberrant vessel growth and its sequelae have been a focus for treat-
ing neovascular AMD (nAMD). The use of argon and krypton photocoagulation 
on CNV was first evaluated by the Macular Photocoagulation Study Group (MPS 
studies) [7, 8], followed by photodynamic therapy (PDT) studied by the Treatment 
of Age-related macular degeneration with Photodynamic therapy (TAP) and 
Verteporfin in Photodynamic Therapy (VIP) study groups [9, 10].
The isolation and discovery of vascular endothelial growth factor (VEGF) as 
the main driver of nAMD led to its targeting and inhibition as treatment [11]. 
This began with intravitreal injections of pegaptanib sodium (Macugen, OSI 
Pharmaceuticals, Melville, NY), a pegylated VEGF165 specific aptamer, which 
demonstrated promising results in clinical studies and received fast-track approval 
from the FDA in 2004 [12]. Shortly thereafter, use of other anti-VEGF agents 
emerged with the positive results of off-label bevacizumab (Avastin, Genentech, 
San Francisco, CA) described in September 2005 [11, 13], which became a cor-
nerstone of therapy for nAMD, along with its truncated Fab counterpart ranibi-
zumab (Lucentis, Genentech, San Francisco, CA), later available in 2006 [14, 15]. 
Subsequently, the soluble VEGF decoy receptor, aflibercept (Eylea, Regeneron, 
Tarrytown, NY) has seen increased usage since its approval in 2011, due to its 
comparable efficacy to the other agents as well as some perceived advantages in 
clinical management with the possibility for less frequent dosing [16]. It has also 
demonstrated variable efficacy in clearing persistent fluid in eyes previously treated 
with bevacizumab or ranibizumab [17, 18]. Indeed, the use of anti-VEGF agents 
proved far superior to previous therapies, including laser photocoagulation and 
photodynamic therapy [7, 10, 15]. These extremely positive results caused a rapid 
paradigm shift in the management of nAMD and anti-VEGF agents quickly became 
the standard of care.
Although the anti-VEGF agent class is clearly superior, there are instances when 
PDT or thermal laser used in combination with anti-VEGF agents is appropriate. A 
commonly reported draw-back of thermal laser in the management of CNV is the 
high incidence of disease recurrence [19–21]. However, Adrean et al. have demon-
strated in a case series of five eyes with peripapillary CNV, with subfoveal extension 
of exudate and fluid, that anti-VEGF therapy pretreatment may better help define 
the CNV area receiving laser treatment by first limiting the size of the CNV then 
causing resolution of the hemorrhage and exudate [22]. Following laser treatment, 
a subsequent anti-VEGF injection is given 1 week later to inhibit pathological CNV 
growth in response to the thermal laser [22]. This robust treatment method dem-
onstrated that all study eyes were free of recurrence at a mean follow-up time of 
24 months with average vision improving from 20/50 to 20/30 (p = 0.0232) [22].
Newer studies are underway examining other therapeutic options for the 
management of nAMD [23, 24].
2. Anti-VEGF treatment protocols and visual results
Three main treatment strategies have been developed to manage nAMD. The 
first method is fixed interval dosing, a mainstay of randomized clinical trials 
(RCT), where patients receive treatments on a monthly, bimonthly or quarterly 
interval based on the anti-VEGF agent. Shortly thereafter, the Pro-Re-Nata 
(PRN) method was introduced, where patients were treated as needed based on 
optical coherent tomography (OCT) status, usually preceded by three monthly 
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anti-VEGF loading doses. Another method developed was the Treat-and-Extend 
regimen (TAE). Patients are typically treated until a dry macula is obtained, and 
then the time interval between injections is gradually increased, usually by one to 
two-week intervals. These distinct treatment methods produce comparable visual 
and anatomic outcomes in the short term (≤1–2 years). However, in the long term 
(≥3 years), small differences in these outcomes are substantially amplified.
2.1 Fixed interval dosing
The treatment of nAMD using anti-VEGF therapy began with fixed interval 
dosing, which is the mainstay of the initial, landmark RCTs. Subjects with CNV 
typically have scheduled examinations with SD-OCT and receive intravitreal injec-
tions every 4 to 6 weeks. Patients may also get fundus photos (FF) and fluorescein 
angiography (FA) initially and at other predetermined time intervals [14].
This treatment strategy is the initial treatment regimen that demonstrated 
superior efficacy compared with previous methods such as thermal laser and 
verteporfin, as well as a largely positive safety profile, in RCTs and clinical prac-
tice. In the seminal anti-VEGF RCTs, namely the Ranibizumab for Neovascular 
Age-Related Macular Degeneration (MARINA), Ranibizumab versus Verteporfin 
for Neovascular Age-Related Macular Degeneration (ANCHOR), and Twelve 
and Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in 
patients with subfoveal neovascular age-related macular degeneration (HARBOR) 
trials, treatment arms with monthly ranibizumab injection demonstrated an aver-
age visual improvement of +6.5 to +11.3 ETDRS letters [14, 15, 25, 26]. Subsequent 
trials such as the ranibizumab and bevacizumab for treatment of neovascular age-
related macular degeneration (CATT) and alternative treatments to inhibit VEGF 
in age-related choroidal neovascularization (IVAN) trials reported, at minimum, 
similar clinical efficacy of ranibizumab and bevacizumab in each of the treatment 
arms (∆ = 1.4 letters CATT 24 months; ∆ = 1.3 letters IVAN 24 months) [27–30]. 
Intravitreal aflibercept reported a composite 8.4 ETDRS letter gain at 52 weeks in 
the VIEW 1 and VIEW 2 RCTs and met non-inferiority criteria when compared 
with ranibizumab treatment arms [16]. Yet one study, the PIER study, evaluated 
fixed interval dosing with ranibizumab, at a greater time interval between injec-
tions and showed poorer overall outcomes compared to monthly treatments. 
Patients were randomized 1:1:1 to receive 0.3 mg ranibizumab, 0.5 mg ranibi-
zumab, and sham injections, respectively, at quarterly intervals [31]. At the end 
of the first year, patients in each of the treatment groups had already experienced 
visual declines below baseline vision [31], and by the end of the second year, 
visual loss was even more dramatic (e.g. −0.2 at 1 year and −2.3 letters at 2 years 
for 0.5 mg ranibizumab vs. onset study vision) [32]. While better than sham injec-
tions, these results were strikingly worse compared to monthly fixed dosing in 
previous RCTs (+6.5 to +11.3 ETDRS letters vs. baseline). Study patients were sub-
sequently rolled-over to monthly injections, and although some vision was able 
to be recovered (+2.9 to +4.3 ETDRS letters), visual acuity (VA) was never able to 
be restored to levels consistent with monthly dosing [32]. This was one of the first 
examples that reduced treatment in a RCT had decreased visual outcomes and that 
more frequent dosing of anti-VEGF agents resulted in better visual outcomes.
Then multiple retrospective studies describing the success of monthly dosed 
anti-VEGF injections were published, with certain retrospective studies demon-
strating efficacy over the long term [33, 34]. For example, Peden et al. retrospec-
tively reported average visual results of 14.0 letters, 12.2 letters and 12.1 letters 
at an average treatment duration of 5, 6 and 7 years, respectively, using a fixed 
monthly injection regimen averaging 10.5 injections per year [34]. However, due 
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to the treatment and potential economic burden, injection fatigue to both patient 
and physician, as well as the concern for systemic arteriothrombotic events (ATEs), 
other treatment strategies have been developed.
2.2 Pro-Re-Nata (PRN) dosing
The first response to fixed interval dosing was the development of a treat as 
needed (PRN) dosing regimen, which gained rapid acceptance after initial RCTs 
evaluating its efficacy at 1–2 years compared favorably to monthly fixed dosing. 
Patients receiving this strategy typically receive loading injections, most commonly 
once per month for 3 months, and then injections are given or held based on exam. 
If patients’ vision and disease stabilize, then injections are held. If there is persistent 
fluid or exudate, anti-VEGF therapy is continued monthly until a “dry” macula 
occurs, typically determined on SD-OCT. Otherwise, changes such as decreased 
vision, new onset fluid or growth of lesion size, among others, as demonstrated 
by clinical exam, OCT, FA or other diagnostic methods typically drive renewal of 
treatment [27, 28].
The HARBOR and CATT trials reported clinically comparable visual gains 
between monthly fixed dosing and PRN study arms at year one [25, 27]. Although 
in the Harbor trial, examining ranibizumab, the PRN arm was unable to meet the 
pre-specified, non-inferiority outcomes even at 1 year compared to fixed-monthly 
injections [25]. On the other hand, even though the CATT study reported worse 
vision in the PRN group in both the bevacizumab or ranibizumab arms, it met the 
non-inferiority criteria compared to fixed monthly dosing [27]. Interestingly, these 
two landmark RCTs had different non-inferiority criteria, differing by only one 
letter [25, 27]. Regardless, by the end of year two, visual outcomes in the PRN treat-
ments arms was significantly worse than the fixed monthly dosed groups in both 
studies (p < 0.05) [26, 28]. In fact, the HARBOR study concluded that at the end of 
12 months, monthly dosing of ranibizumab proved superior over PRN dosing [26]; 
and, the CATT study likewise summarized that “[PRN] resulted in less gain in VA, 
whether instituted at enrollment or after 1 year of monthly treatment [28].” The 
IVAN study, later conducted in the United Kingdom, concluded that visual out-
comes using the PRN method were “equivalent” to continuous treatment (−0.4 let-
ters, 95% Cl, −2.40 to 1.70) in the first year of evaluation [29]. However, by the end 
of the second year, they reported that the “reduction in the frequency of retreat-
ment resulted in a small loss of efficacy irrespective of drug,” and demonstrated 
that discontinuous treatment resulted in 1.6 letters lost compared to monthly fixed 
dosing, although this was not statistically significant (p = 0.18) [30]. These, argu-
ably small, differences were further amplified when this treatment methodology 
was continued over the long term. Two landmark extension studies of RCTs demon-
strated this effect: The Five-Year Outcomes with Anti-Vascular Endothelial Growth 
Factor Treatment of Neovascular Age-Related Macular Degeneration (CATT-5) 
trial and the Seven-year Outcomes in Ranibizumab-treated Patients in ANCHOR, 
MARINA, and HORIZON: a Multicenter Cohort Study (SEVEN-UP). In these two 
studies, most patients were transitioned or maintained on a PRN schedule follow-
ing the conclusion of their respective RCTs. By the end of year 5 of the CATT-5 
study, patients on average lost 3 ETDRS letters from baseline and 11 letters from 
the 2-year endpoint of the original CATT study [35]. Moreover, 20% of eyes had 
vision 20/200 or worse compared to only 6% at study baseline, which improved to 
5% in years 1 and 2 [35]. Overall, 36.4% of eyes lost ≥5 letters from baseline and 
54.6% of eyes lost ≥5 letters from the end of year 2 [35]. In fact, nearly 24% of eyes 
lost ≥15 letters baseline and 29% lost ≥15 letters from the original study conclusion 
[35]. In the SEVEN-UP study, 37% of eyes had vision 20/200 or worse at the end of 
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7 years, with 34% of eyes losing ≥15 letters for an average decline of 8.6 letters from 
ANCHOR or MARINA baseline [36]. Strikingly, this was a change of −19.8 letters 
from the peak vision obtained at the end of the ANCHOR and MARINA trials [36]. 
In fact, most eyes lost vision at the end of the SEVEN-UP study when compared to 
any of the presenting or exiting vision of its preceding studies (56.9% vs. MARINA 
or ANCHOR entry; 84.6% vs. MARINA or ANCHOR exit) [36]. Similar trends 
have been observed in clinical practice and documented in multiple retrospective 
studies, demonstrating good clinical outcomes in the near term which deteriorated 
over time, commonly below baseline levels. In a study by Rasmussen et al., 192 eyes 
receiving PRN injections had an improvement of 3.4 letter above baseline at the end 
of 1 year, which regressed to 1.4 letters at the end of year 4 [37]. This was one of the 
few PRN studies that demonstrated an average final vision above baseline, although 
this was still not statistically significant [37]. Others, such as those by Gillies 
et al. [38], Zhu et al. [39], Haddad et al. [40], the PACORES study group [41] and 
Westborg et al. [42] recorded average visual losses from as little as −4.3 letters to as 
much as −25.4 letters from peak visual gains, when studied over the long term.
2.3 Treat-and-Extend (TAE) and Treat-Extend-Stop (TES) methods
Although initially well received, small deficiencies in visual and anatomic 
outcomes under the PRN strategy were amplified both in RCTs and clinical prac-
tice, particularly when patients required anti-VEGF injections over the long term. 
Thus, in response, a graduated treatment protocol, termed “Treat-and-Extend” 
(TAE), along with its variation, the “Treat-Extend-Stop” regimen developed by 
Adrean et al. [43], was created to improve patient outcomes while keeping the 
benefits of reduced treatment burden. Due to the success of this method, it is 
currently the most widely used treatment protocol of retinal specialists in the 
United States [44]. Patients treated with this strategy are typically treated with a 
minimum of 3 monthly loading doses until there is clinical resolution of fluid and 
SD-OCT demonstrates a “dry” macula [43]. Treatments are then lengthened by 
1–2-weeks based on evaluation at each visit [43]. If a “dry” macula is maintained on 
SD-OCT, then the time interval is increased to a typical maximum of 10–12 weeks 
[43]. If at any time patients experience a decrease in vision or increase in exudation 
as quantified on SD-OCT, then treatment intervals are adjusted, usually decreas-
ing by 1–2 weeks, to adequately control the disease process [43]. Some patients 
can reach maximum extension, and therefore continue receiving treatment every 
10–12 weeks indefinitely; other patients never reach maximal extension, but 
instead require constant adjustment or continuous treatment at shorter intervals 
[43]. If patients are determined to be failing one anti-VEGF agent after 3–6 intra-
vitreal injections, the anti-VEGF agent is typically changed.
The TES strategy was developed for patients achieving a maximal extension 
to further decrease treatment burden [43]. Using the TES method, patients who 
reached a maximum extension of 12 weeks then receive 2 additional injections, each 
12 weeks apart, with an FA performed at the second 12-week visit to evaluate the 
CNV [43]. Patients are then examined 12 weeks later [43]. If the macula was “dry” at 
that point, as determined by SD-OCT, patients are then considered to be in disease 
remission and further injections are held [43]. Next, patients are carefully monitored 
for any signs of disease recurrence with a monitoring phase beginning 4 weeks later 
[43]. Evaluation intervals are then progressively lengthened at 2-week intervals 
until 12 weeks are reached, at which time patients are then monitored indefinitely at 
quarterly intervals [43]. If at any time, patients notice decreased vision or an increase 
in metamorphopsia, they are instructed to return immediately to the clinic for re-
initiation of treatment, and the TES protocol is restarted from the beginning [43].
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In RCTs and clinical practice, the TAE method has demonstrated visual out-
comes similar to monthly fixed dosing at a decreased increased injection frequency, 
and superior to those reported using the PRN method. In the Comparison of 
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration 
Accord to LUCAS Treat-and Extend Protocol (LUCAS) trial by Berg et al., beva-
cizumab and ranibizumab were found to be equivalent with an average of 7.9 and 
8.2 letters gained, respectively, at the end of the first year [45]. In the second year, 
bevacizumab and ranibizumab continued to demonstrate efficacy with aver-
age visual improvements of 7.4 and 6.6 letters from baseline, respectively [45]. 
Interestingly, a greater number of injections were given in the bevacizumab group 
than in the ranibizumab group [45]. Around the same time, Wykoff et al. published 
a Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular 
Age-Related Macular Degeneration [46]. Wykoff et al. demonstrated at the end of 1 
year that TAE dosing of 0.5 mg ranibizumab resulted in similar outcomes compared 
to fixed monthly dosing, with average visual gains of 10.5 and 9.2 letters respectively 
[46]. The comparative efficacy between TAE and fixed monthly administration has 
also been described in numerous other studies, both retrospectively and prospec-
tively. For example, Chen et al. demonstrated in a retrospective analysis that eyes 
undergoing monthly vs. TAE treatment at 1 year on average had a visual difference 
of −0.5 letters (p = 0.81) [47]. Additionally, Abedi et al. demonstrated in a prospec-
tive cohort study of 120 eyes, average visual gains of 9.5 letters and 8.0 letters at 12 
and 24 months, respectively, which were comparable to those of the pivotal clinical 
trials [48]. These visual outcomes may also be maintained over the long term. For 
example, in a retrospective cohort study by Mrejen et al., 210 study eyes, with a 
retention rate of 62.9%, at an average of 3.5 years, had visual improvement of 20/90 
from study baseline to 20/75, or approximately one line of improvement (p < 0.05) 
with an average of 8.3 injections per year [49]. Perhaps the longest studies evaluating 
this method are those performed by Adrean et al., specifically using the TES varia-
tion. In one study, patients received TES treatment for an average of nearly 3 years 
until the disease was controlled to remission, and patients were transitioned to 
quarterly follow up, as described previously, without injections [43]. At this point, 
the average visual improvement was approximately +7.5 ETDRS letters, improving 
from 20/70 to 20/50, with 60% of eyes achieving 20/40 vision or better [43]. At 
study conclusion, accounting for CNV disease recurrence and re-initiation of treat-
ment, a total of 38.1% of eyes gained 3 or more lines of vision, whereas only 2 eyes 
of a single patient (4.8%) lost 3 lines of vision due to development of geographic 
atrophy [43]. In another study, Adrean et al. demonstrated that long-term treatment 
of 71 study eyes with nAMD, using the TES protocol, resulted in average visual gains 
of 9.7 letters over an average treatment period of 6.5 years [50]. Notably, this visual 
improvement was maintained over an average follow-up period of 8 years, with 
only a slight decrease to a final average visual improvement of 8.7 letters [50]. The 
percentage of eyes gaining 3 or more lines of vision at final follow-up in this study at 
8 years, was 35.2%; conversely, 9.9% of eyes lost 3 or more lines [50]. In fact, these 
visual outcomes are similar to the proportion of eyes gaining at least 3 lines of vision 
found in monthly fixed dosing RCTs, such as MARINA (33.3% with 0.5 mg ranibi-
zumab) [14], ANCHOR (41% with 0.5 mg ranibizumab) [15], and HARBOR (34.5% 
with 0.5 mg ranibizumab) [26] at the final study endpoint of only 2 years.
Both RCTs and retrospective studies using the TAE/TES method have demon-
strated superior visual outcomes compared to PRN studies. In a systematic review by 
Rufai et al., which included the assessment of 748 eyes undergoing the TAE protocol, 
the one-year BCVA improvement was 8.9 letters, compared to the 3.5 letters reported 
by Chin-Yee et al. in a separate systematic review regarding the PRN method [51]. 
Head to head studies, such as those by Chin-Yee et al., demonstrated an average 10.4 
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letter improvement in the TAE group vs. 5.4 letters in the PRN group at 12 months, 
with the TAE group receiving about 3.5 more injections on average [52]. Likewise, 
in a study by Oubraham et al., average visual acuity was greater in TAE treated eyes 
compared to PRN treated eyes by 8.5 letters with an average of 2.7 more injections 
[53]. Interestingly, the number of follow-up visits was similar (8.5 vs. 8.8, TAE vs. 
PRN, p = 0.2085) [53]. The most interesting studies might be those conducted by 
Hatz et al. and Cohen et al. As with the rescue effect observed in the patients rolled-
over from PRN to monthly dosing in the PIER trials, patients transitioning from 
the PRN to the TAE method demonstrated improved vision despite having a greater 
number of office visits in the PRN group [54, 55]. Although there is no long-term 
head-to-head comparison study between TAE/TES vs. PRN treatment methods in 
RCTs or private practice, a comparison of these outcomes individually reveals that 
the TAE/TES method is superior. RCTs, such as the CATT-5 and SEVEN-UP stud-
ies, along with many retrospective studies employing the PRN method beyond an 
average follow-up time of 3 years (up to 7 years) have demonstrated average visual 
changes of +1.4 to −19.3 letters from baseline vision [35–42]. Conversely, prospective 
and retrospective data have reported visual increases of 5–9.7 letters for similar time 
intervals in eyes managed by a TAE/TES strategy [43, 49, 50].
3. Potential mechanisms of management strategies for disease and  
visual outcomes
Various factors have been implicated in the variation of visual outcomes for eyes 
with nAMD managed by anti-VEGF therapy [6]. For example, older age or male 
gender has been associated with increased exudative disease and the need for retreat-
ment [56]. However, recent studies have suggested that some factors, such as initial 
presenting vision, are predictive of the long-term visual gains [57]. Additionally, 
other groups have examined CNV lesion type and demonstrated that there was a dif-
ferential response to anti-VEGF therapy and visual outcomes [14, 15, 49]. Therefore, 
it appears that the optimization of these factors may lead to more favorable responses 
in patients’ visual outcomes, especially over the long term.
Shah and Del Priore in a large meta-analysis described that patients’ present-
ing vision contributed to as much as 90% of the final visual outcomes obtained 
using anti-VEGF therapy [57]. Poorer presenting vision was typically due to longer 
delays before the initial presentation to the physician, with patients reporting a 
longer duration of symptoms before seeking care [57]. The greater the delay was 
prior to initiating anti-VEGF therapy, the worse the final achievable vision [57]. 
Interestingly, they also noted that patients with worse initial vision also had greater 
amounts of active exudation and more commonly presented with type-2 classic 
CNV [57]. It is generally accepted that in the typical course of the disease, if left 
untreated, type-1 occult lesions often progress to mixed and, subsequently, clas-
sic CNV [58]. Over time, uncontrolled disease activity and exudation perpetually 
cause damage to the neurosensory retina and RPE, ultimately leading to subretinal 
fibrosis and irreversible vision loss.
Distinct lesions respond differently to anti-VEGF therapy. Early RCTs, for 
example, when comparing the results achieved from monthly dosing of 0.5 mg 
ranibizumab in the MARINA study for minimally classic or occult lesions to the 
predominantly classic lesions evaluated in the ANCHOR trials, demonstrated that 
visual gains were greater in the classical CNV study [14, 15]. While this seems to 
contradict the findings of Shah and Del Priore [57], this is because patients with 
subretinal fibrosis or signs of advanced macular degeneration were excluded. 
Additionally, patients’ baseline vision in the ANCHOR trial had to be better than 
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20/320 to be included in the trial, which limited many patients with advanced exu-
dative disease [15]. While visual gains were better realized in the ANCHOR study, 
possibly due to poorer presenting vision, a ceiling effect was likely encountered 
in the MARINA study. For example, the average presenting vision of the 0.5 mg 
ranibizumab arm of the ANCHOR study was 47.1 ± 13.2 letters [15], whereas it was 
53.7 ± 12.8 letters in MARINA [14], a difference of nearly 7 letters. At the end of 
year one, the study eyes in the ANCHOR study had gained an average of 11.3 letters 
in the 0.5 mg ranibizumab group [15] compared to 7.2 letters in the MARINA study 
[14], for average final VA of 58.4 vs. 60.9 letters respectively [14, 15]. Other reasons, 
such as the location of the CNV or exudation in relation to the fovea may also play a 
factor. Classic lesions outside of the fovea with subfoveal leakage and exudate may 
have better visual outcomes since the CNV itself is not subfoveal. As the fluid and 
exudate dissipate with therapy, the subfoveal architecture remains largely intact 
with preservation of the central photoreceptors and retinal pigment epithelium, 
allowing for increased visual gains.
As described previously, there are relatively few studies examining the long-term 
treatment results of anti-VEGF therapy. Those describing the PRN strategy have 
been the most numerous, while those examining the TAE/TES or monthly dosing 
regimens are substantially fewer. There are even fewer studies that characterize 
lesion type or subtype and their response to anti-VEGF therapy over 2–3 years. One 
study, by Mrejen et al., examined the response of anti-VEGF treatment adminis-
tered using a TAE strategy in eyes with different CNV lesion subtypes [49]. Occult 
lesions were found to have the best initial presenting vision, which was maintained 
throughout 4 years, although these patients also received an average of 0.6–2.2 more 
injections compared to other groups (p < 0.05) [49]. Preservation of vision tends to 
be greater in occult or mixed lesions as opposed to classic lesions [49]. These results 
were replicated in a similar study by Berg et al., which demonstrated that longer-
term anti-VEGF therapy using a TAE method resulted in better visual maintenance 
in eyes with occult or mixed lesions over classic lesions or retinal angiomatous 
proliferation (RAP) [59]. Together with the evidence described above, reporting 
that eyes with delayed initial presentation and worse baseline vision having greater 
evidence of active exudation as well as the progression from type-1 occult to type-2 
classic lesions, it is apparent that early diagnosis and thorough control of nAMD 
should result in the best possible visual outcomes. Otherwise, a CNV left untreated 
or inadequately treated may lead to progressive retinal damage, which generally 
manifests as increased fluid or exudation, which then leads to end-stage disease such 
as atrophic and fibrovascular scarring, ultimately resulting in decreased vision.
As we have previously noted, slightly worse vision due to PRN treatment in 
short-term studies has resulted in substantially worse vision over the long term 
when compared to monthly fixed or TAE/TES dosing strategies, even when baseline 
characteristics are otherwise comparable. This may be, in fact, due to the reac-
tive nature of the PRN strategy, leading to considerable delays in recognition of 
increased disease leading to suboptimal treatment. Due to the inherent difficulty 
in scheduling office visits and the unreliability of patients to report increased 
disease (caused by several factors, such as the subtlety of symptoms confounded 
by the vision in the fellow eye), by the time the patient presents for follow-up, even 
if scheduled ahead of time, new onset or progression of active disease may have 
already occurred. It may be, in fact, that the fewer injection numbers reported by 
PRN studies, particularly in the long term, are not a result of better disease control, 
but are instead demonstrative of missed opportunities for adequate disease control.
Indeed, the number of injections is a key factor associated with final visual 
outcomes [60]. This may be due to greater numbers of injections maintaining a 
therapeutic level of VEGF inhibition in the eye. In a study by Lumbroso et al., vessel 
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proliferative cycling of CNV in the presence of anti-VEGF activity was examined 
[61]. The proliferation of aberrant vessels in CNV appears to cycle through a series 
of predictable stages after anti-VEGF inhibition [61]. Pruning begins within 24 h 
of initial anti-VEGF injection and progresses to maximal inhibition at 6–12 days 
[61]. As anti-VEGF levels fall, the sprouting of new vessels and angiogenic leak-
age may then develop anywhere from 20 to 50 days later [61]. Interestingly, with 
increasing numbers of anti-VEGF injections, likely maintaining steady inhibitory 
concentrations within the eye, the time between each proliferative cycle lengthens 
[61]. Neovascular vessel burden decreases and, instead, the central vessels from 
which they sprout and open increase in size [61]. This process may also explain why 
untreated occult disease may eventually progress to type-2 lesions, followed by 
fibrovascular scarring and irreversible vision damage. Due to the reactive nature of 
the PRN strategy described above, poor inhibition on this mechanism of neovascu-
lar proliferation likely occurs. For example, after transitioning all original treatment 
groups in the CATT, MARINA and ANCHOR trials to the PRN method for long-
term treatment, the number of eyes with residual fluid at the end of the CATT-5 
and SEVEN-UP trials was 68 and 83%, respectively [35, 36]. Moreover, 24.5% of 
CATT-5 study eyes were found to have leakage on FA [35]. Likewise, 48% of eyes 
had active or probable leakage of FA in the SEVEN-UP study [36]. Interestingly, 
despite 68% of eyes having intraretinal or subretinal fluid, and nearly half of eyes 
with leakage on FA, only 46% of eyes were receiving ongoing treatment at the end 
of the SEVEN-UP study [36]. Although it is unclear which of the factors described 
above may have contributed to the visual decline of the study patients in these two 
RCTs, the mismatch between eyes with active disease or persistent fluid/exuda-
tion and those that were receiving active treatment suggests that adequate disease 
follow-up and control may not have been well established. Moreover, this is com-
plicated by the fact that, as reported in both SEVEN-UP and CATT-5 studies, the 
subretinal fluid itself was not significantly associated with decreased vision, while 
intra-retinal fluid was [35, 36]. However, the SEVEN-UP study group suggested that 
subretinal fluid may be relevant in the context of generally uncontrolled neovas-
cular disease progression [62]. Along with hemorrhage and exudation, permanent 
damage to the neurosensory retina and surrounding structures may also lead to 
macular atrophy, one of the strongest drivers of decreased vision in the long-term 
treatment of nAMD [62]. The CATT study group, on the other hand, proposed that 
subretinal fluid may, in fact, be protective against the development of geographic 
atrophy [63]. However, these two studies differ in their respective definitions 
of atrophic disease. The CATT study group suggested that the atrophic macular 
lesions they describe may be clinically indistinguishable from those arising from 
non-neovascular origins, mainly geographic atrophy [63]. Macular atrophy may be 
a separate entity since it lacks the classic anatomical features of geographic atrophy 
[62]. Thus far, it appears that timeliness and greater numbers of injections generally 
lead to better anatomical and visual outcomes. Future studies further elucidating 
these factors may help better optimize treatment strategies.
When comparing the number of injections patients received, the average 
number of injections received was greatest in the monthly dosed regimens, fol-
lowed by the TAE/TES method, and finally PRN. For example, Peden et al. reported 
an average of 10.5 injections per year at 7 years, using the monthly fixed interval 
dosing [34]. Adrean et al. in their consistent long-term anti-VEGF study, utiliz-
ing the TES strategy, were performing 9.6 injections per year at 6.5 years and 8.1 
injections per year at the final follow-up at 8 years [50]. Conversely, RCTs utilizing 
the PRN method reported an average of 5.1 injections per year in the CATT-5 study 
[35] and 2 injections per year in the SEVEN-UP study after exit from the HORIZON 
follow-up trial [36]. Interestingly, in a subgroup of patients that received more 
Visual Impairment and Blindness
10
injections (3.2 per year) in the SEVEN-UP trial, their vision was significantly better 
than other study participants [36]. As described earlier, the number of injections 
has been demonstrated to be an independent factor positively contributing to 
visual improvement. Again, this phenomenon may be explained in the context of 
increased injections leading to maintenance of adequate inhibition of VEGF, which 
in turn, inhibits vessel growth and increases the time for neovascular vessel pro-
liferation cycles. While some studies demonstrate that the PRN method has fewer 
injections than TAE/TES dosing at a 1-year endpoint, they have similar number of 
visits, with poorer visual outcomes [64].
Taken together, these lines of evidence suggest that the improper timing of the 
PRN method to detect and treat disease, as well as the subtherapeutic dosing of 
anti-VEGF agents due to less frequent injections, leads to a greater exudation, hem-
orrhage, and progressive macular damage, ultimately resulting in poorer vision. 
Monthly dosing, on the other hand, is superior for controlling disease. However, 
this method may not scale as the population ages and the incidence of nAMD rises. 
Fixed monthly dosing may lead to overtreatment, injection fatigue, as well as 
increased costs and the potential for increased risk of adverse events. The TAE/TES 
method, with progressively lengthening treatment and observation times, individu-
alized to each patient, may maintain adequate intravitreal anti-VEGF levels which 
allows for the lengthening of neovascular vessel proliferation cycles. The long-term 
visual outcomes of the TAE/TES method compare favorably to the fixed dosing 
method, with fewer office visits and injections. Future therapeutic advancements 
may further optimize nAMD management.
4. Dosing strategy and effect on disease activity, recurrence and  
visual outcomes
Various studies have attempted to define characteristics of disease control and 
make better assessments for when to continue treatments consistently or pos-
sibly discontinue treatment. The most commonly used characteristics are changes 
in visual acuity and the presence or absence of retinal fluid, typically based on 
SD-OCT data regardless of the dosing strategy utilized [65, 66].
A consensus article by Amoaku et al. attempts to characterize the degree of 
response eyes have to anti-VEGF therapy [66]. Eyes are categorized as good, 
partial, poor or non-responders. Good responders are free of fluid or have a central 
retinal thickness (CRT) reduced by >75% following the initial loading phase of 
therapy, typically the first 3 monthly injections. Visually, these eyes demonstrate an 
improvement of >5 ETDRS letters or achieve greater than 70 total ETDRS letters, 
if a ceiling effect is present. Partial responders have less CRT reduction (25–75%) 
and may have some persistent subretinal or intraretinal fluid. Visual improve-
ment is generally limited to 1–4 letters gained. Poor responders have even less CRT 
reduction (0–25%) as well as persistent fluid on SD-OCT. Visual acuity is typically 
unchanged from baseline to a loss of −4 letters. Finally, non-responders have 
unchanging or increasing CRT, fluid or pigmented epithelial detachment (PED), 
with eyes losing 5 or more letters. Management of nAMD can be stratified based 
on these characteristics. For example, good and partial responders may continue 
their current anti-VEGF regimen if their vision or morphology is maintained. If 
there is decreased vision or indicators of poorer morphology, the time interval 
between treatment should be reduced, and if treatment has been maintained at 
4-week intervals without an improvement in morphology, a switch in anti-VEGF 
agents is needed. Other studies have characterized response based on lesion type, 
concluding that occult and mixed lesions generally respond better to anti-VEGF 
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therapy than classic or RAP lesions [49, 59]. Moreover, not all retinal fluid is equal, 
as some groups have suggested that subretinal fluid is protective against geographic 
atrophy [63]. Nonetheless, many agree that achieving a dry macula is necessary to 
prevent retinal damage over the long term and is essential for the improvement and 
preservation of vision.
When considering the dosing regimen, Amoaku et al. suggested that more 
frequent dosing tends towards improved visual outcomes, likely due to proactive 
disease control that is not realized in PRN methods which often result in under-
treatment [66]. Other factors such as antibody neutralization and tachyphylaxis 
may also affect the success of anti-VEGF treatment regardless of factors such as 
presenting vision or morphology [66]. Therefore, it appears that a patient’s response 
to anti-VEGF therapy is a complex interplay between multiple factors that are 
attributable intrinsically to the patient as well as their treatment history.
One key factor in a patient’s treatment history affecting visual outcomes is 
the degree of disease control. However, there is loose language surrounding the 
topic of active disease progression or disease recurrence. Many studies have 
described recurrence as any new onset of fluid or exudation regardless of time, 
thus implicitly suggesting that active disease is controlled as soon as the macula 
is deemed “dry”. Other studies use the term “disease recurrence” to mean new 
onset CNV or exudation after disease remission, for example, a minimum time 
criterion of 4 months with no evidence of fluid or exudation (“active disease”) 
[40, 43]. At present, there is no formal definition accepted. This is problematic 
because, as discussed earlier, neovascular vessel proliferative cycling times may be 
lengthened with successive anti-VEGF injections, leading to clearing of fluid, but 
the underlying disease may not be entirely controlled. Thus, those that conclude 
active disease is controlled after the fluid has been eliminated from the macula 
after a single injection may be mistaken, and the clearing of fluid observed may 
be short-lived. Indeed, this fact is most concerning for patients undergoing 
anti-VEGF treatment with a PRN regimen, as follow-up visits which demonstrate 
“absence” of disease and subtle visual changes may ultimately cause delays in 
treatment and progressive retinal damage. This phenomenon is less likely to be 
present in TAE/TES or monthly fixed dosing strategies since injections are more 
frequent and scheduled. However, a lack of consensus definition confuses the 
reported outcomes in literature and serves to make comparisons between studies 
more challenging. Given that previous in vitro studies have demonstrated that 
new pathologic vessels may develop after a single anti-VEGF injection of up to 
62 days later [61], true disease remission logically should be at minimum outside 
of this time. Thus, disease remission may be defined as no fluid recurrence within 
4 months and that at this point the disease is considered quiescent. If fluid occurs 
outside of the 4-month period, it is likely that a true recurrence of nAMD has 
occurred. However, any increase of subretinal or intraretinal fluid that occurs 
during active treatment in the TAE/TES protocol should be defined as an increase 
in disease activity and the time interval should be decreased accordingly, depend-
ing on the amount of increased disease activity. If patients are in the loading or 
maintenance phase of a TAE/TES protocol and are in the 5–8 week treatment 
range, then the time interval between injections should be reduced by 1–2 weeks. 
If patients are being treated at the 10–12 week range and there is a small amount 
of increased exudation, then the time interval again may be reduced by 2 weeks. 
However, if there is a significant increase in disease activity, then the time interval 
should be reduced more aggressively, potentially even restarting the TAE/TES 
protocol. If patients continue to have increased exudation and the time interval 
between anti-VEGF injections has been decreased to the 4–6 week range, then 
likely the anti-VEGF agents needs to be switched [43, 45, 50] If patients are being 
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treated with a PRN methodology, and there is increased fluid at a time interval of 
less than 4 months without treatment, again this should be considered increased 
disease activity. If increased exudation occurs outside of 4 months, this should be 
considered a true recurrence.
Reports on true CNV disease recurrence are currently limited. Two retrospec-
tive studies have reported this phenomenon. In the first, Haddad et al. utilized 
a PRN dosing method in 132 eyes over an average follow-up of 7.75 years [40]. 
Eighty-three (63%) eyes experienced long-term remission without requiring treat-
ment for 1 year at least one time during the duration of the study [40]. However, 
among them, 42 (51%) eyes experienced a true recurrence of CNV [40]. The 
average vision of the entire cohort improved 5.0 letters after 1 year compared to 
baseline [40]. However, by the end of 7.75 years, this visual improvement was not 
maintained and decreased to −3.4 letters below baseline, a total loss of 8.4 letters 
[40]. Conversely, in a study by Adrean et al., 143 of 385 eyes (37.3%), treated with a 
TES protocol, experienced long-term disease remission with a minimum treatment 
cessation period of 4 months [43]. Prior to this time, these eyes were treated with 
a TES protocol for an average of 33 months [43]. The average initial presenting 
vision was 20/70 and improved to 20/50 at the completion of the treatment phase, 
or approximately 7.5 ETDRS letters [43]. The average time to true disease recur-
rence was 14 months later and occurred in 42/143 (29.4%) eyes [43]. At this point, 
average vision decreased to 20/60, with 54.8% of eyes experiencing a recurrence 
without a decrease in vision [43]. However, once eyes were restarted on the TES 
protocol, average vision recovered to 20/50 and was maintained throughout the 
remaining average 27 months of follow-up [43]. Although the criteria for remis-
sion of disease are different between these two studies, the average time observed 
of quiescent disease not requiring treatment was around 1 year [40, 43]. Notably 
different, however, is that the final vision of eyes treated with the more robust TES 
method was better and was able to be salvaged should a recurrence occur [40, 43]. 
This is likely due to the undertreatment of active disease that is commonly experi-
enced from PRN methods, even if eyes demonstrate signs of good response [66]. 
Eyes demonstrating good response under a PRN method may require more vigilant 
monitoring over a greater period of time before one may conclude that active 
disease has been controlled. On the other hand, eyes that have received more robust 
treatment under the TES method may be carefully monitored at longer intervals 
if good response has been demonstrated throughout the course of treatment for 
active disease.
5. Conclusion
In this chapter, the three main treatment strategies to treat nAMD were pre-
sented and discussed. The first strategy examined was the fixed dose treatment 
method, where anti-VEGF agents are given on a routine basis, typically monthly 
or bimonthly after an initial loading phase. The advantage of this method is that 
it has been proven successful in multiple landmark clinical trials and patients may 
expect potentially the best visual outcomes. Fixed dosing disadvantages include the 
lack of individualized treatment with potentially no endpoint and the possibility 
of being overtreated. There is a potential for more episodes of endophthalmitis 
with more injections given and the chance for systemic effects, although this is 
still debated. The next treatment strategy presented was the PRN methodology, 
where patients are typically given a loading dose of three monthly anti-VEGF 
injections and then monitoring is begun once the macula is dry. Patients are then 
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treated only after the detection of new-onset decreased vision or increased fluid. 
The advantage of this treatment methodology is that patients receive fewer injec-
tions with potentially fewer systemic and ocular side effects. However, there is the 
potential for delayed detection of decreased visual or anatomic damage, increasing 
the risk for undertreatment with this methodology. Visual results of this method 
have definitely proven inferior compared to other dosing regimens, particularly 
over the long term. The final treatment strategy presented was the treat-and-extend 
regimen with its variant treat-extend-stop. After three loading doses of anti-VEGF 
therapy for nAMD, patients are then extended by 2-week intervals once a dry 
macular is achieved. In some patients, the therapy is stopped after patients are given 
two injections 12 weeks apart and held at the third 12-week interval, after which 
careful monitoring of patients’ visual function and macular changes is begun. This 
personalized anti-VEGF regimen offers the greatest potential for success. The TAE/
TES regimen may be the best choice for managing patients with nAMD, particularly 
over the long term, regardless of the choice of the anti-VEGF agent. The TAE/
TES method provides comparable visual results to monthly fixed interval dos-
ing, however at a decreased treatment burden and has the potential for decreased 
adverse events. This proactive and patient-specific method also has many benefits 
over the PRN strategy, including but not limited to greater visual improvement, 
better maintenance of visual improvement over the long term, increased potential 
for disease remission, fewer rates of CNV recurrence, and the ability for recovery of 
vision after recurrence.
This chapter also discussed the definition of recurrence versus increased 
disease activity. Increased disease activity was defined as increased intraretinal or 
subretinal fluid with potentially decreased vision and increased metamorphopsia 
that occurred during active treatment. If patients fail to respond to any one agent 
after 4–6 monthly anti-VEGF injections and still have worsening subretinal or 
intraretinal fluid, these patients may meet the definition of primary treatment 
failure and the anti-VEGF agent can be switched. If patients are in the extension 
part of the TAE/TES protocol and there is increased fluid and exudation, the time 
interval between treatments should be reduced by 1–2 weeks if there is minimally 
increased exudation. If there is a significant increase in exudation or hemorrhage, 
then the time interval should be decreased more aggressively, potentially restart-
ing the TAE/TES protocol. Patients with nAMD likely require at least 1 year of 
therapy, extended to 12-week treatment intervals, before treatment cessation 
is considered since there is a subset of patients of whom are delayed responders 
and may demonstrate increased vision over a longer time frame. A true disease 
recurrence would be defined as one where a CNV shows increased exudation and 
hemorrhage after 4 months of no treatment and careful monitoring. This true 
recurrence rate was found to be 29% in the TES protocol and patients with a true 
recurrence had overall visual outcomes comparable to their vision at treatment 
cessation after re-initiation of anti-VEGF treatment. It is likely that partial, poor 
or non-responders are more inclined to receive consistent treatment at time 
intervals in the 4–8 week range, and these patients’ visual acuity over the long 
run may be best maintained with this dosing interval. This conservative calibra-
tion strategy thus strives to proactively optimize the treatment regimen to the 
patients’ response.
Additional studies, particularly prospective randomized clinical trials evaluat-
ing the response of various treatment methodologies over the long term as well as 
those exploring the mechanisms underlying clinical outcomes, will help further 
optimize anti-VEGF therapy and spur the development of novel methods for the 
treatment of nAMD.
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